List of Revlimid drug patents
Revlimid is owned by Celgene.
Revlimid contains Lenalidomide.
Revlimid has a total of 15 drug patents out of which 0 drug patents have expired.
Revlimid was authorised for market use on 27 December, 2005.
Revlimid is available in capsule;oral dosage forms.
Revlimid can be used as use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, in combination with dexamethasone, use of revlimid (lenalidomide) for the treatment of previously treated follicular lymphoma in combination with a rituximab product, use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, as maintenance following autologous hematopoietic stem cell transplantation (auto-hsct), use of revlimid (lenalidomide) for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib, use of revlimid (lenalidomide) for treatment of patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities, use of revlimid (lenalidomide) for the treatment of previously treated marginal zone lymphoma in combination with a rituximab product; use of revlimid (lenalidomide) for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib; use of revlimid (lenalidomide) for the treatment of previously treated follicular lymphoma in combination with a rituximab product, use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, in combination with dexamethasone, wherein those patients have not received previous treatment for multiple myeloma.
The generics of Revlimid are possible to be released after 08 March, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7855217 | CELGENE | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Nov, 2024
(1 year, 7 months from now) | |
| US7465800 | CELGENE | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Apr, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7189740 | CELGENE | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
Apr, 2023
(8 days from now) | |
| US8404717 | CELGENE | Methods of treating myelodysplastic syndromes using lenalidomide |
Apr, 2023
(8 days from now) | |
| US9056120 | CELGENE | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
Apr, 2023
(8 days from now) | |
| US9155730 | CELGENE | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent |
May, 2023
(a month from now) | |
| US8648095 | CELGENE | Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor |
May, 2023
(a month from now) | |
| US9101621 | CELGENE | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
May, 2023
(a month from now) | |
| US8530498 | CELGENE | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione |
May, 2023
(a month from now) | |
| US9101622 | CELGENE | Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone |
May, 2023
(a month from now) | |
| US9393238 | CELGENE | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent |
May, 2023
(a month from now) | |
| US7968569 | CELGENE | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(6 months from now) | |
| US8492406 | CELGENE | Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(6 months from now) | |
| US7468363 | CELGENE | Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(6 months from now) | |
| US8741929 | CELGENE | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas |
Mar, 2028
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | May 28, 2026 |
Drugs and Companies using LENALIDOMIDE ingredient
Market Authorisation Date: 27 December, 2005
Treatment: Use of revlimid (lenalidomide) for treatment of patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality with or...
Dosage: CAPSULE;ORAL
REVLIMID family patents
110
United States
31
China
30
Canada
29
European Union
28
Japan
19
Australia
17
Korea, Republic of
15
New Zealand
14
Mexico
10
Israel
10
Hong Kong
9
Denmark
9
Portugal
9
Spain
8
South Africa
7
Taiwan, Province of China
6
Slovenia
6
Norway
6
Brazil
6
Poland
5
Cyprus
4
Austria
4
Russia
4
Costa Rica
4
Argentina
4
ME
3
Hungary
3
Germany
3
Peru
3
RS
3
Ukraine
2
Croatia
2
Iceland
2
Ecuador
1
OA
1
Morocco
1
AP
1
Yugoslavia
1
Chile
1
Georgia
1
Luxembourg
1
EA
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic